- Home
- CNMD vs JANX Comparison
CNMD vs JANX Comparison
Compare CNMD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNMD | JANX |
|---|---|---|
| Founded | 1970 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 840.4M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNMD | JANX |
|---|---|---|
| Price | $35.00 | $13.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $46.25 | ★ $47.00 |
| AVG Volume (30 Days) | 383.9K | ★ 862.8K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $1,374,724,000.00 | $10,000,000.00 |
| Revenue This Year | $0.82 | N/A |
| Revenue Next Year | $5.48 | N/A |
| P/E Ratio | $23.26 | ★ N/A |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $32.13 | $12.12 |
| 52 Week High | $60.30 | $35.34 |
Technical Indicators
Market Signals| Indicator | CNMD | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 35.27 |
| Support Level | $33.21 | $13.15 |
| Resistance Level | $38.60 | $14.64 |
| Average True Range (ATR) | 1.50 | 0.48 |
| MACD | -0.13 | -0.10 |
| Stochastic Oscillator | 44.03 | 5.26 |
Price Performance
Historical ComparisonAbout CNMD CONMED Corporation
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.